A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)

• Status: Recruiting
• Trial end date: 2026-04-01
• Target enrollment: 0
• Participant gender: All

Summary

A new drug called azeliragon could be used to treat patients with COVID-19 but the researchers don't know. In this study, they are learning the effects of azeliragonon patients hospitalized for COVID-19.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Salim S. Hayek

Criteria

Inclusion Criteria:

• Patients with a laboratory confirmed Severe Acute Respiratory Syndrome (SARS)-coronavirus 2 (CoV-2) infection and admitted primarily for the treatment of COVID-19. Co-administration of FDA approved antivirals or monoclonal antibodies is permitted.

• Patients admitted to the hospital within the previous 48 hours (from time of admission to initial treatment dose.)

• Provide informed consent to participate in the study (by participant or legally-acceptable representative).

Exclusion Criteria:

• Patients for whom intubation within 24 hours of admission is considered likely.

• Severe chronic respiratory disease, defined by any supplemental oxygen requirement prior to incident COVID-19 infection.

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3x upper limit of normal (ULN), OR total serum bilirubin >2x ULN.

• Patients who were receiving dialysis as a regular treatment at the time of admission. (Participants are not excluded for historic need for dialysis.)

• Chronic liver disease with Child-Pugh class B of (7 to 9) or higher.

• Patients with an electrocardiogram (ECG) corrected QT interval (QTc) > 500 ms.

• Patients requiring treatment with strong inhibitors of CYP2C8

• Females of childbearing potential who are pregnant, breastfeeding, and/or not using a highly-effective method of contraception (consistent with local regulations regarding the methods of contraception for those participating in clinical studies, including willingness to use 2 acceptable forms of contraception from screening until after the end of drug treatment. Acceptable forms include tubal ligation, male latex condom with or without spermicide, partner's vasectomy, diaphragm with spermicide, intrauterine device, cervical cap/sponge with spermicide, contraceptive sponge, female condom, hormonal contraceptive including oral, transdermal, vaginal ring, subcutaneous injection, or implanted rod.)

• Allergy to azeliragon or formulation excipients in the azeliragon or placebo capsule.

• Concurrent participation in another device or drug trial.

• Any other condition, including abnormal laboratory values that, in the judgment of the investigator, could put the participant at increased risk, or would interfere with the conduct or planned analysis of the study.